HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

BMC Gastroenterology

Volumn 12, Issue , 2012, Pages

  Pellicelli, Adriano M ^a   Romano, Mario ^b   Stroffolini, Tommaso ^c   Mazzoni, Ettore ^d   Mecenate, Fabrizio ^e   Monarca, Roberto ^f   Picardi, Antonio ^g   Bonaventura, Maria E ^h   Mastropietro, Cristina ^c   Vignally, Pascal ⁱ   Andreoli, Arnaldo ^a   Marignani, Massimo ^j   D'Ambrosio, Cecilia ^a   Miglioresi, Lucia ^a   Nosotti, Lorenzo ^k   Mitidieri, Olga ^l   Gentilucci, Umberto V ^g   Puoti, Claudio ^l   Barbaro, Giuseppe ^m   Barlattani, Angelo ⁿ   Furlan, Caterina ^c   Barbarini, Giorgio ^o   more..

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b SANDRO PERTINI HOSPITAL   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^e Liver Unit Villa Betania Hospital   (Italy)

^f BELCOLLE HOSPITAL   (Italy)

^g UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^h SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

ⁱ ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k Medicine of Migration National Institute for Migrant Health and Poverty   (Italy)

^l Department of Internal Medicine   (Italy)

^m SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁿ ASL RM/A   (Italy)

^o FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

more..

Author keywords

Antiviral therapy; Genotype 1a; HCV genotype 1 subtypes; Pegylated interferon; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; HYPOTHYROIDISM; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHUMAN; PROGNOSIS; RNA ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS TYPING;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84869050086     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-12-162     Document Type: Article

References (22)

1. McHutchison JG, Everson GT, Gordon SC, et al. PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838. 10.1056/NEJMoa0806104, 19403902.
2. Kwo PY, Lawitz EJ, McCone J, et al. SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716. 10.1016/S0140-6736(10)60934-8, 20692693.
3. Fried MW, Shiffman ML, Reddy K, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982. 10.1056/NEJMoa020047, 12324553.
4. Hadziyannis SJ, Sette H, Morgan TR, et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
5. Cheng WS, Roberts SK, McCaughan G. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 2010, 53:616-623. 10.1016/j.jhep.2010.04.024, 20619475.
6. Bruno S, Cammà C, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Hepatol 2004, 41:474-481.
7. Rizzetto M, Colombo M, Ascione A, et al. Effectiveness of hepatitis C virus treatment in real life practice: a prospective observational multicenter study in Italy (PROBE). J Hepatol 2008, 2(48):S311.
8. Legrand-Abravanel F, Colson P, Leguillou-Guillemette L, et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J MedVirol 2009, 81:2029-2035.
9. Nicot F, Alric L, Barange K, et al. Influence of genotype 1 subtypes on the virus response to Peg interferon alpha-2a plus ribavirin therapy. J Med Virol 2011, 83:437-444. 10.1002/jmv.21976, 21264864.
10. Rosina F, Tosti ME, Borghesio E, et al. PEG-IFN for chronic hepatitis C in clinical practice: the prospective phase of the AIFA study. Dig Liv Dis 2012, 44S:s12.
11. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435. 10.1002/hep.1840010511, 7308988.
12. Dienstag JL, McHutchinson J. American Gastroenterological association technical review on the management of hepatitis C. Gastroenterology 2006, 130:231-264. 10.1053/j.gastro.2005.11.010, 16401486.
13. Zein NN, Rakela EL, Krawitt KR, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 1996, 125:634-639.
14. Zein NN. Clinical significance of hepatitis C virus genotypes. ClinMicrobiol Rev 2000, 13:223-235.
15. Nevens E, Van Vlierberghe H, D'Heygere E, et al. BERNAR-1 Study Group. A randomized open label, multicenter studyevaluating the efficacy of peginterferon alfa 2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patient. Acta Gastroenterol Belg 2010, 73:223-228.
16. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J GastroenterolHepatol 2007, 22:832-836.
17. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462. 10.1053/j.gastro.2009.11.055, 20006612.
18. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593. 10.1056/NEJMoa0808010, 19625712.
19. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is nore effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010, 138:116-122. 10.1053/j.gastro.2009.10.005, 19852964.
20. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon alfa2a plus ribavirin vs peginterferon alfa2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010, 138:108-115. 10.1053/j.gastro.2009.08.071, 19766645.
21. Rumi MG, Aghemo A, Prati GM. Comparative trials of peginterferon alfa-2a and peginterferon alfa-2b for chronic hepatitis C. J Viral Hepatol 2012, 19:37-41.
22. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongestpretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 2010(139):120-129.